According to Gram Research analysis, about 10% of gynecologic tumors have high levels of a protein called FOLR1, and these tumors tend to be more aggressive with worse outcomes. Researchers found that FOLR1-positive cancers were more likely to be advanced-stage, larger, higher-grade, and associated with shorter progression-free survival. This discovery matters because new drugs targeting FOLR1 are being developed, and identifying which patients have FOLR1-positive tumors could help doctors choose better treatments.
Researchers studied a protein called FOLR1 found in women’s reproductive cancers to understand how it might help doctors treat these diseases better. They examined 306 tumors from 304 patients and found that about 10% had high levels of FOLR1. This protein was most common in a type of ovarian cancer called high-grade serous carcinoma. The study showed that tumors with high FOLR1 levels tended to be more aggressive and harder to treat. These findings could help doctors identify which patients might benefit from new targeted treatments that specifically attack FOLR1.
Key Statistics
A 2026 study of 304 patients with 306 gynecologic tumors found that 10.1% had high FOLR1 expression, with 64.5% of FOLR1-positive cases being high-grade serous ovarian cancers.
According to research reviewed by Gram, gynecologic tumors with high FOLR1 expression were significantly associated with advanced clinical stage, larger tumor size, higher histologic grade, and shorter progression-free survival.
A 2026 analysis of 304 gynecologic cancer patients found that endometrial tumors with FOLR1 overexpression had a significantly higher rate of TP53 mutations (P=0.013) and were associated with poor histologic grade and larger tumor size.
Research shows that FOLR1 overexpression in gynecologic cancers correlated with positive PD-L1 expression (P=0.012), suggesting these tumors may evade immune system detection.
The Quick Take
- What they studied: Whether a protein called FOLR1 appears in women’s reproductive cancers and whether it’s connected to cancer aggressiveness and treatment options.
- Who participated: 304 patients with 306 gynecologic tumors (mostly ovarian and uterine cancers). Researchers tested tissue samples to measure FOLR1 protein levels.
- Key finding: About 10% of tumors had high FOLR1 levels, and these tumors were more aggressive with worse outcomes. Most FOLR1-positive tumors were high-grade serous ovarian cancers (64.5%).
- What it means for you: If you have a gynecologic cancer, testing for FOLR1 might help your doctor choose better treatment options. New drugs targeting FOLR1 are being developed. However, this is early research—talk to your oncologist about whether FOLR1 testing is right for your situation.
The Research Details
Researchers collected tissue samples from 304 cancer patients with 306 tumors and used a special staining technique called immunohistochemistry to measure FOLR1 protein levels in the cancer cells. They defined ‘high FOLR1’ as when at least 75% of cancer cells showed moderate to strong FOLR1 staining. They then compared FOLR1 levels to other cancer characteristics like tumor grade, size, stage, and genetic mutations to see which features were connected.
The study looked at different types of gynecologic cancers including ovarian cancer, uterine cancer, and fallopian tube cancer. Researchers also examined whether FOLR1 was connected to other important cancer markers like PD-L1 (which affects immune response) and p53 mutations (which affect cancer aggressiveness).
This approach allowed doctors to understand which patients might benefit from new treatments that target FOLR1 specifically. The findings help identify a ‘biomarker’—a measurable sign that helps predict how a cancer will behave and respond to treatment.
Understanding which cancers have high FOLR1 is important because pharmaceutical companies are developing new drugs that specifically attack FOLR1. If doctors can identify patients whose tumors have high FOLR1, they can offer these targeted treatments to the patients most likely to benefit. This is more effective than giving all patients the same treatment.
This study examined a reasonable number of patient samples (304), which gives the findings more credibility than smaller studies. The researchers used a standardized testing method (immunohistochemistry) that’s widely accepted in pathology. However, this is a single-center study looking backward at existing tissue samples, so the findings need confirmation in larger, prospective studies. The study doesn’t prove that FOLR1 causes cancer aggressiveness—only that they’re associated. Results may vary in different patient populations.
What the Results Show
Of the 306 tumors studied, 31 (10.1%) had high FOLR1 expression. The majority of FOLR1-positive tumors were high-grade serous ovarian cancers (64.5%), which are among the most aggressive gynecologic cancers. Other cancer types with FOLR1 included uterine serous carcinoma, endometrial cancer, and low-grade ovarian cancers.
Tumors with high FOLR1 were significantly more aggressive. They were associated with advanced cancer stage, larger tumor size, higher grade (meaning more abnormal-looking cells), and spread to lymph nodes. Patients with FOLR1-positive tumors had shorter progression-free survival, meaning their cancers came back sooner.
In endometrial (uterine) cancers specifically, FOLR1-positive tumors were larger, higher grade, and had mutations in the p53 gene—a gene that normally prevents cancer. Interestingly, all endometrial tumors with PTEN mutations (another cancer-related gene) were negative for FOLR1, suggesting these might be different cancer subtypes.
FOLR1 overexpression also correlated with other important cancer markers. Tumors with high FOLR1 were more likely to have positive PD-L1 expression (which helps cancer hide from the immune system) and intact mismatch repair proteins (which affects how the cancer mutates).
The study found that FOLR1-positive tumors were more likely to have positive estrogen receptor (ER) expression, which is relevant because some cancers respond to hormone-blocking treatments. In endometrial cancers, FOLR1-positive tumors had lower progesterone receptor (PR) expression, which may indicate a different cancer subtype. The connection between FOLR1 and p53 mutations in endometrial cancers was particularly strong, suggesting these tumors share common molecular features.
FOLR1 has recently become recognized as a therapeutic target in advanced cancers, and this study confirms that FOLR1 is present in a meaningful subset of gynecologic cancers. Previous research identified FOLR1 as important in ovarian cancer, and this study confirms that high-grade serous ovarian cancers are the most common FOLR1-positive tumors. The association between FOLR1 and poor prognostic factors (aggressive features) aligns with what researchers expected, supporting the idea that FOLR1 could be a useful treatment target.
This study looked backward at existing tissue samples rather than following patients forward over time, which limits what we can conclude. The study was conducted at a single medical center, so results might differ in other populations. The researchers didn’t follow patients to see if FOLR1 actually predicted treatment response—they only looked at associations with cancer characteristics. The study doesn’t prove that high FOLR1 causes worse outcomes, only that they occur together. Additionally, the definition of ‘positive FOLR1’ (≥75% of cells) was chosen by the researchers and may need adjustment based on future clinical trials.
The Bottom Line
If you have a gynecologic cancer (especially ovarian or uterine cancer), ask your doctor whether FOLR1 testing is available and appropriate for your situation. If your tumor is FOLR1-positive, discuss whether you’re eligible for clinical trials testing new FOLR1-targeting drugs. These drugs are still being developed, so availability is limited. Continue standard cancer treatments as recommended by your oncology team. (Confidence: Moderate—this is early research that needs confirmation in clinical trials.)
Women diagnosed with gynecologic cancers, particularly high-grade serous ovarian cancer, uterine serous carcinoma, and endometrial cancer, should be aware of FOLR1 testing. Oncologists and gynecologic pathologists should consider FOLR1 testing as part of comprehensive tumor profiling. Patients with advanced-stage disease or recurrent cancer may benefit most from FOLR1-targeted treatments. This research is less immediately relevant for patients with early-stage, low-grade cancers.
FOLR1-targeting drugs are still in clinical trials, so widespread availability may be 2-5 years away. If you’re eligible for a clinical trial, you might see treatment effects within weeks to months. For standard treatments, discuss realistic timelines with your oncologist based on your specific cancer type and stage.
Frequently Asked Questions
What is FOLR1 and why does it matter for cancer treatment?
FOLR1 is a protein found on some cancer cells that new drugs can target. About 10% of gynecologic cancers have high FOLR1 levels. Testing for FOLR1 helps doctors identify patients who might benefit from new targeted treatments specifically designed to attack this protein.
If I have ovarian cancer, should I get tested for FOLR1?
If you have advanced ovarian cancer, especially high-grade serous type, ask your oncologist about FOLR1 testing. This study found FOLR1 in 64.5% of FOLR1-positive cases. Testing can help determine if you’re eligible for new clinical trials using FOLR1-targeting drugs.
Does high FOLR1 mean my cancer is more aggressive?
High FOLR1 expression is associated with more aggressive cancer features like advanced stage, larger size, and higher grade. However, association doesn’t prove causation. Talk to your oncologist about what FOLR1 status means for your specific cancer and treatment options.
Are there drugs available now that target FOLR1?
FOLR1-targeting drugs are still in clinical trials and not yet widely available. However, several pharmaceutical companies are developing these treatments. Ask your oncologist about clinical trial eligibility if your tumor is FOLR1-positive.
What does it mean if my endometrial cancer has a p53 mutation and high FOLR1?
This study found that endometrial cancers with high FOLR1 frequently have p53 mutations, suggesting a specific cancer subtype. This combination indicates more aggressive disease. Discuss with your oncologist whether this affects your treatment plan or clinical trial eligibility.
Want to Apply This Research?
- If you have a gynecologic cancer, track your tumor marker levels (like CA-125 for ovarian cancer) monthly or as recommended by your doctor. Record whether you’ve had FOLR1 testing done and the results. Note any clinical trials you’re enrolled in and track side effects or response indicators.
- Request FOLR1 testing as part of your comprehensive tumor profiling if you haven’t had it done. Ask your oncologist specifically whether you’re eligible for FOLR1-targeted clinical trials. Keep detailed records of all your genetic and biomarker test results in one place for easy reference at appointments.
- Set reminders for regular oncology appointments and tumor marker testing. Track progression-free survival milestones (time until cancer recurrence) and compare your outcomes to your baseline. Monitor clinical trial databases quarterly to see if new FOLR1-targeting drugs become available for your cancer type.
This research describes laboratory findings about FOLR1 protein in cancer tissue samples. It does not establish that FOLR1 testing or FOLR1-targeting drugs are currently standard treatment. FOLR1-targeting medications are still in clinical trials and not yet FDA-approved for routine use. If you have a gynecologic cancer diagnosis, consult with your oncologist about whether FOLR1 testing is appropriate for your situation and whether you’re eligible for clinical trials. Do not make treatment decisions based on this research alone. This article is for educational purposes and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.